Call Scheduled for Wednesday, December 23 at 8:00 a.m. Eastern Time
EMERYVILLE, Calif., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will host a conference call and webcast on Wednesday, December 23, 2015, at 8:00 a.m. ET/ 5:00 a.m. PT, to provide a company update.
|U.S./Canada Dial-in Number:||(844) 215-3280|
|International Dial-In Number:||(484) 747-6383|
Interested parties may access a live audio webcast of the conference call via the Adamas Pharmaceutical website at http://ir.adamaspharma.com/events.cfm. A replay of the call will be available on the Adamas website later in the day. The replay will be available for approximately one month following the call.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly owned product candidate, for the treatment of levodopa-induced dyskinesia associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric™ and Namenda XR®, two approved products with Forest Laboratories Holdings Limited, an indirect wholly owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.
For questions, please contact: Julie Wood Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. Phone: 510-450-3528
Source:Adamas Pharmaceuticals, Inc.